156424-47-4 Usage
Description
2-methyl-6-phenylthieno[3,2-d]pyrimidin-4-ol, commonly known as Cilostazol, is a pharmaceutical compound with vasodilatory and antiplatelet properties. It functions as a selective inhibitor of cyclic guanosine monophosphate (cGMP) phosphodiesterase type 3 (PDE-3), which aids in the dilation of blood vessels and enhancement of blood flow. This medication is utilized in the treatment of intermittent claudication, a condition marked by leg pain and cramping during physical activity due to decreased blood flow.
Uses
Used in Pharmaceutical Industry:
2-methyl-6-phenylthieno[3,2-d]pyrimidin-4-ol is used as a medication for the treatment of intermittent claudication. It is employed as a vasodilator to improve blood flow and as an antiplatelet agent to prevent blood clot formation, thereby alleviating symptoms associated with reduced blood flow in the legs.
As part of a comprehensive treatment plan, 2-methyl-6-phenylthieno[3,2-d]pyrimidin-4-ol is taken orally and may be combined with exercise therapy and other medications to manage the symptoms of intermittent claudication effectively. However, it is essential to consider potential side effects such as headache, diarrhea, and dizziness, and to evaluate its suitability for individuals with specific medical conditions before prescribing.
Check Digit Verification of cas no
The CAS Registry Mumber 156424-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,4,2 and 4 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 156424-47:
(8*1)+(7*5)+(6*6)+(5*4)+(4*2)+(3*4)+(2*4)+(1*7)=134
134 % 10 = 4
So 156424-47-4 is a valid CAS Registry Number.
156424-47-4Relevant articles and documents
Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists
Norman,Chen,Chen,Fotsch,Hale,Han,Hurt,Jenkins,Kincaid,Liu,Lu,Moreno,Santora,Sonnenberg,Karbon
, p. 4288 - 4312 (2007/10/03)
Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.
